The possibility of a suicide attempt is inherent in psychotic illnesses and bipolar disorder, and close supervision of high-risk patients should accompany drug therapy.
Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including ABILIFY; use caution in patients at risk for aspiration pneumonia.
Physicians should advise patients to avoid alcohol while taking ABILIFY.
Strong CYP3A4 or CYP2D6 inhibitors increase ABILIFY drug concentrations when used concomitantly.
CYP3A4 inducers decrease ABILIFY drug concentrations when used concomitantly.
Commonly observed adverse reactions (greater than or equal to 5 percent incidence and at least twice the rate of placebo for adjunctive ABILIFY vs adjunctive placebo, respectively):
-- Adult patients with major depressive disorder: akathisia (25 percent vs
4 percent), restlessness (12 percent vs 2 percent), insomnia (8 percent
vs 2 percent), constipation (5 percent vs 2 percent), fatigue
(8 percent vs 4 percent), and blurred vision (6 percent vs 1 percent).
Please see FULL PRESCRIBING INFORMATION, including Boxed WARNING, for ABILIFY.
About Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd.
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. are collaborative partners in the development and commercialization of ABILIFY in the United States and major European countries.
ABILIFY was discovered by Otsuka Pharmaceutical Co., Ltd. Founded in
1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with
the corporate philosophy: "Otsuka - people creating new products for better
health worldwide." Otsuka researches, develops, manufactures and markets
innovative and original produ
|SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.|
Copyright©2007 PR Newswire.
All rights reserved